Close
Nordic 9Nordic 9

New Leaf Venture Partners (investor - Venture Capital)

United States nlvpartners.com
See something wrong or missing? Let us know
Offices:New York

New Leaf Venture Partners is a venture capital firm funding the healthcare revolution by investing exclusively in companies revolutionizing healthcare.

Average round investment:44M USD
Average number per year:1.0
Distribution: 2020 (1)
Portfolio companies: United Kingdom ReViral
Mostly invests in: United Kingdom United Kingdom (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to New Leaf Venture Partners

Name Criteria
Hong Kong CR-CP Life Science Fund
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Green Sands Equity
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden AP4 - Fjärde AP-fonden
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Bengt Julander
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Spain Columbus Venture Partners
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Spain HealthEquity
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Roche Venture Fund
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Tekla Capital Management
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands LSP (Life Sciences Partners)
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
Switzerland Novartis Venture Fund
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Top